Fresenius stock slips as UBS reiterates Buy rating and 43.52-euro target

Published on 09/17/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock on Xetra trades lower at 45.93 euros as of September 17, 2026, while UBS reiterates a Buy rating with a 43.52-euro target. Barclays remains at Overweight with a higher 57.50-euro target from September 16, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius SE & Co. KGaA stock (ISIN DE0005785604) traded at 45.93 euros on Xetra around midday on September 17, 2026, down 0.5 percent from the prior close as investors digested mixed analyst signals on the healthcare group.

Analyst views: UBS cautious, Barclays more upbeat

According to finanzen.ch on September 17, 2026, UBS AG maintains a Buy rating on Fresenius with a price target of 43.52 euros, a level that now sits slightly below the current Xetra price of 45.93 euros.

As Headtopics reported on September 16, 2026, Barclays has reiterated its Overweight rating on Fresenius and kept its higher price target of 57.50 euros, implying upside of about 25.2 percent compared with the September 17, 2026 Xetra price.

Recent performance and valuation context

Per earlier Xetra data cited by Ad-hoc News, Fresenius stock closed at 45.39 euros on Xetra on September 15, 2026 and climbed to 46.08 euros during the September 16, 2026 session, so the latest 45.93-euro level represents a modest pullback of 0.3 percent from that intraday high.

At the 45.93-euro price as of September 17, 2026, Fresenius also trades roughly 20.6 percent below the consensus price target of 57.50 euros cited by Barclays, underscoring that the market still prices in execution risks despite the Buy and Overweight recommendations.

Fundamentals: Q2 2026 figures underpin analyst stance

According to Ad-hoc News, analyst commentary referencing MarketScreener highlights that Fresenius delivered second-quarter 2026 results ahead of estimates and raised parts of its guidance for 2026, framing the current analyst ratings in the context of a positive earnings surprise.

As summarized by the same analysis, Q2 2026 revenue and earnings were described as beating consensus expectations, which contributed to a stronger outlook and supported the Barclays decision to stick with an Overweight rating and a 57.50-euro target, even as UBS works with a more cautious 43.52-euro price objective.

Upcoming catalyst: Q3 2026 results in early November

Per the financial calendar information referenced by Ad-hoc News, Fresenius is scheduled to publish its third-quarter 2026 results on November 4, 2026, giving investors a clear next date to reassess whether the company can sustain the momentum from Q2 2026.

The combination of a near-term earnings date and a double-digit percentage gap between the current share price and key analyst targets makes the upcoming November 4, 2026 release a focal point for measuring whether recent operational improvements can translate into further share-price gains.

Fresenius stock price snapshot

Fresenius stock most recently traded at 45.93 euros on Xetra at around 12:57 p.m. local time on September 17, 2026, down 0.5 percent on the day, with intraday moves reflecting investor reactions to the fresh UBS analysis and the earlier Barclays reaffirmation.